{
  "schema_version": "1.3.1",
  "doc": {
    "doc_id": "2d6386ac464dda5e92f456c020347478",
    "title": "Jefferies",
    "source_uri": "25.9月 普通个人版/9.1 普通个人版/Jefferies/FY25 - The Warmth of the SunFY25 - The Warmth of the Sun_2025-08-28",
    "language": "en",
    "timestamps": {
      "ingested_at": "2025-10-26T12:19:18.445716",
      "extracted_at": "2025-10-26T12:19:18.445732"
    },
    "extraction_run": {
      "vision_model": "deepseek-ai/DeepSeek-OCR",
      "synthesis_model": "rule-based-engine",
      "pipeline_steps": [
        "ocr",
        "rule_extraction",
        "figure_vision"
      ],
      "processing_metadata": {
        "pages_processed": 15,
        "successful_pages": 15,
        "date": "2025-08-28",
        "publication": "25.9月 普通个人版/9.1 普通个人版/Jefferies",
        "authors": [],
        "markdown_cleaning": {
          "removed_sections": 3,
          "removed_paragraphs": 7,
          "reduction_ratio": 0.12243155371158965
        },
        "input_relative_path": "25.9月 普通个人版/9.1 普通个人版/Jefferies"
      }
    }
  },
  "passages": [
    {
      "passage_id": "49d1224ed4465f64",
      "text": "Australia | Biotechnology  Clinuvel",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "209177fc8fc38872",
      "text": "CUV treats sunlight and pigment- related diseases. CUV's longer- term catalysts include growth in the Americas, as well as ongoing clinical trials in vitiligo. FY25 volume growth was c1%. That said, we forecast volume growth of 4% for FY26E, as CUV will enter two EU geographies in FY26E. We expect first results from the CUV105 Phase 3 vitiligo trial in 2HCY26.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "362a7cde3353842f",
      "text": "Two opportunities: 1) under- penetrated EPP market with no competitors at present; and 2) currently in Phase 3 clinical trial with vitiligo, which affects c0.75% of the US population with current treatment options suboptimal. We believe that CUV currently is treating only c4% of the EPP patients in larger countries of Europe, Americas and Asia (c15% of EU and Americas), a situation which should be progressively corrected through ongoing local approvals. Vitiligo is a regimentation disease with a large total addressable market of up to cUS\\\\$500m in the first two years of entry into the US market. Given Phase 2 trial results, we believe afamelanotide may eventually offer a more definitive, full- body solution than current standards of care.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "dd57dacf6ab121b3",
      "text": "FY25 normalised net profit of \\(\\Delta\\) 36.2m increased c2% from the previous corresponding period (pcp), with higher costs. FY25 sales revenue increased c6% on pcp to A\\\\$86.4m. This translated to an estimated c1% increase in volume in FY25 compared to pcp. We forecast 4% volume growth for FY26E.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "72b3a3c894d25adc",
      "text": "Opportunity continues in the US. The number of patients who have received the drug has grown with the rise in Specialty Centers that are trained and accredited to administer Scenesee. The number of accredited North American centers has risen from 93 at December 2024 to 104 at end June 2025 (120 continue to be planned for extra geographic coverage by end 2025). In addition, the number of national and local private insurers has previously grown to more than 110.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "8b5b6d4bf5014928",
      "text": "Clinuvel recently reported preliminary results from Scenesee EPP study - equivalent safety profile between adults and adolescents. In a completed CUV 052 study, CUV noted biochemical data in adolescents was similar to the historical range in healthy adult volunteers. Final analyses of data from CUV052 are expected in 2HCY25. CUV believes that the data will support Scenesee label extension filing in 2HCY25. The CUV052 trial is important as new patients with EPP are usually diagnosed around age 12, according to industry experts, and hence would ideally standard treatment as children.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "610f1ac9b71d7389",
      "text": "FY26E EPS decreases by c15%, FY27E EPS decreases by c20%. Changes to forecasts include: 1) updating for forecast sales into the EPP market in FY26E+, particularly for the US EPP market, and assuming a slower growth rate; 2) Updating FY26E+ % GPM in line with FY25; 3) updating FY26E+ COGS in line with FY25; and 4) Updating other cost lines for FY26E+ in line with FY25.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "4e128679b3686891",
      "text": "FY16 A\\\\$37.25 (from A\\\\$40). We use our risk- weighted valuation of the CUV current EPP rollout and vitiligo opportunity as our price target.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "7836b16a286c4581",
      "text": "TARGET I ESTIMATE CHANGE",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "518753bebb50b986",
      "text": "RATINGBUYPRICEAUD12.53*PRICE TARGET | % TO PT+ AUD37.25 (AUD40.00) | +197%52W HIGH-LOWAUD15.99 - AUD9.41FLOAT (%) | ADV MM (USD)78.8% | 1.24MARKET CAPAUD631.3M | $409.4MTICKERCUV AU",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "2daf1f14e7307376",
      "text": "\\\\*Prior trading day's closing price unless otherwise noted.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "a72970731311c781",
      "text": "FY (Jun)CHANGE TO JEFEJEF vs CONS20262027REV-11%-14%EPS-15%-21%-3%2026 (AUD)1Half2HalfEPS+0.28+0.55PREV0.290.68",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "62e2c50a9e5af6cf",
      "text": "Figure 1 - Clinuvel - risk weighted valuation, by indication",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "2c44b76e8b8cc5ac",
      "text": "Source: Jefferies estimates",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "fa93f874dd2d944f",
      "text": "Figure 2 - Clinuvel - implied number of implants sold",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "5c9c7366466f4a99",
      "text": "Source: Company data, Jefferies estimates",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "695ce3749f106516",
      "text": "FY (Jun)2024A2025A2026E2027ERev. (MM)88.795.0104.4111.7Net Profit35.636.241.644.9EPS0.700.720.830.89FY P/E17.9x17.5x15.2x14.1x",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "3fa42484d9bd9a9b",
      "text": "Please see analyst certifications, important disclosure information, and information regarding the status of non-US analysts on pages 10 - 15 of this report. \\\\* Jefferies (Australia) Pty Ltd",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "a270922e095dcc0f",
      "text": "CUV is not without risks, but there is the chance for meaningful upside should its Scenesce product be reimbursed more widely for EPP and approved for use in vitiligo. Obviously, CUV's major potential stumbling block is further positive late- stage clinical trial results and then regulatory approval in vitiligo. That said, if successful, CUV would likely gain a large amount of market share in a disease in which current treatment options are suboptimal, in our view. Hence, we believe this is an attractive investment opportunity for investors with a higher risk appetite.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "f6c6d3e3fa19cf3d",
      "text": "Risk/Reward - 12 Month View",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "dd232087ca0c8dcf",
      "text": "Our base case price target uses our risk- weighted valuations for the near- term opportunities in the CUV pipeline. In terms of valuation, there are several major potential commercial opportunities for CUV that we value: 1) EPP; 2) vitiligo; DNA repair; and Acute Ischaemic Stroke treatment. Scenesce for EPP has already been approved in the EU and US.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "e85cfe8110fdc520",
      "text": "Our upside case price target is a non- risk weighted valuation for our valuation of CUV's base- case opportunities.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "b39d1ff0cc2214c5",
      "text": "Our downside case price target assumes: 1) the clinical trial in vitiligo fails; and 2) a \\(50\\%\\) lower uptake of Scenesce for the treatment of EPP (by volume) in the larger global markets than we currently forecast due to increased competition.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "dee265a09a2467c8",
      "text": "Pricing is a major issue. Device and drug pricing has always been tied to several social considerations of ESG, such as customer relationships, demographic changes, and social awareness, and it has continually been among the major measures of reputation and regulatory risk.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "ac94000c64de1421",
      "text": "1) No targets for reducing the greenhouse gas emissions.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "7f27c4be6fa7ed78",
      "text": "2) Sustainability focus area for the business. Executive KMPs have specific sustainability measures included in the compensation framework. Targets have been set with transparent performance hurdles for the following ESG criteria: A) On labour standards, CUV supports a safe and flexible workplace and a positive work-life balance; B) aims to recruit from as diverse a pool of candidates possible; and C) has a formal ESG reporting practice.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "196736d4248c6ccc",
      "text": "How is the Board planning for succession of some of its key managers and personnel?",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "2e30e421513b39b5",
      "text": "2) How does CUV ensure that its suppliers are fit for purpose?",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "cae0e531f325bbe4",
      "text": "3) How does CUV continue to work towards extending regulatory approval for Scenesce?",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "e280c11e160bfdb6",
      "text": "ESG Sector Deep Dive Update: Australian Healthcare",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "d00e180ad202ab9c",
      "text": "Figure 3-Clinivel-Expanded Summary Table (ASm)",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "e4df94d7cf9430b0",
      "text": "Year-end 30 Jun (ASm)FY24AFY25AFY26EFY27EFY28ERevenue8995104112417EBITDA45425155219EBIT44415054218Normalised NPAT36364245159JEF NPAT/consensus (%)nana98%89%155%Full diluted norm EPS0.700.720.830.893.16EPS growth on pcp (%)18.22.815.17.9254.3EV/EBITDA (x) (JEF)9.89.57.15.80.8EV/EBIT (x) (JEF)10.19.87.35.90.8FD normalised P/E (x) (JEF)17.617.415.114.03.9Dividend yield (%)0.40.40.50.51.8ROE17.615.014.914.033.9Net debt/equity (%)net cashnet cashnet cashnet cashnet cash",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "6d61eeffbde62e3d",
      "text": "Source:Jefferies data,Factset,IRESS",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "a56f04445cdcf494",
      "text": "CUV's longer- term catalysts include growth in the Americas, as well as ongoing clinical trials in vitiligo. FY25 volume growth was \\(c1\\%\\) . That said, we forecast volume growth of \\(4\\%\\) for FY26E, as CUV will enter two EU geographies in FY26E. We expect first results from the CUV105 Phase 3 vitiligo trial in 2HCY26.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "5725ed0703550e9e",
      "text": "Changes to forecasts include: 1) updating for forecast sales into the EPP market in FY26E+, particularly for the US EPP market, and assuming a slower growth rate; 2) Updating FY26E+ % GPM in line with FY25; 3) updating FY26E+ COGS in line with FY25; and 4) Updating other cost lines for FY26E+ in line with FY25. FY26E EPS decreases by \\(c15\\%\\) , FY27E EPS decreases by \\(c20\\%\\) .",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "5532dc77fbd982f5",
      "text": "Figure 4-Clinivel- Changes to forecasts (USSm)",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "37438c7359a9f488",
      "text": "FY25AFY26EFY27EFY28EPrevRevDiff (%)PrevRevDiff (%)PrevRevDiff (%)RevDiff (%)PrevRevDiff (%)Operating Revenue (ASm)95.486.4(9.5)109.495.8(12.4)121.9103.0(15.5)431.6408.5(5.3)EBITDA (ASm)49.042.5(13.4)64.751.0(21.3)74.155.5(25.2)241.5219.2(9.3)EBIT (ASm)47.741.3(13.4)63.249.7(21.4)72.654.2(25.4)240.0217.9(9.2)NPAT (ASm)38.636.2(6.3)49.341.6(15.6)57.244.9(21.4)174.4159.1(8.8)EPS (c)75.771.8(5.2)96.982.6(14.7)112.289.2(20.5)342.5315.9(7.8)DPS (c)5.05.00.07.06.0(14.3)6.06.00.014.022.057.1Net op cashflow (ASm)42.441.1(3.2)53.946.1(14.5)57.044.5(22.0)174.0158.4(9.0)",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "4a8dcc7ba3c164f9",
      "text": "Source:Jefferies estimates,company data",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "4e9f6a8fcf2ae3b1",
      "text": "FY25 sales revenue increased \\(c6\\%\\) on pcp to A\\$86.4m. The main drivers of the result were solid FY25 revenue growth, offset by higher costs than expected (mostly opex, in line with preparation for a potential vitiligo indication for Scenesce). FY25 normalised net profit of A\\$36.2m increased \\(c1.5\\%\\) from the previous corresponding period (pcp). FY25 normalised EPS of A\\$0.718 increased \\(c3\\%\\) on pcp. FY25 operating cash flow was A\\$41.1m.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "aee20fcb195acaa8",
      "text": "Figure 5-Number of EPP patients treated as a \\(\\%\\) of total in larger markets",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "7d775956fd97888a",
      "text": "CUV FY25A revenue (A$m)86.6A$/EUR exchange rate0.58Implied CUV FY25A revenue (EURm)50.4Assume manufacturer price of EUR14.1K per implantAssume 5 implants per patientHence, number of EPP patients treated in FY25A714No. of EPP pts treated as a % of EU/Am./ROW total (%)4.3%No. of EPP pts treated as a % of US/EU total (%)14.5%",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "a7ddfa8d0a77431f",
      "text": "Source:Company data,Jefferies estimates",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "2cd1147ee04eef4b",
      "text": "In the EU, CUV is undertaking a clinical study (CUV052) to add data to the existing marketing authorization dossier as part of a regulatory application to include adolescent patients to the approved indication for Scenesce. The number of accredited North American centers has risen from 93 at end December 2024 to 104 at June 2025 (120 continue to be planned for extra",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "e12be7775b55df3d",
      "text": "geographic coverage by end CY25). CUV expects progress across several clinical programs with afamelanotide:",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "4a23cd28ab8066a5",
      "text": "- Vitiligo - CUV previously updated its ongoing Phase 3 vitiligo study (CUV105) protocol. The CUV105 study aims to demonstrate that combination therapy Scenesse and NB-UVB therapy provides better repigmentation than NB-UVB monotherapy. Patients assigned the NB-UVB monotherapy appeared less motivated to start or complete the 20-week study and follow-up period. Consequently, now all patients receiving monotherapy and completing the study have access to subsequent Scenesse combination therapy. To us, this implies the combination therapy arm is progressing well compared to monotherapy. The primary and secondary endpoints, including those evaluating depigmentation of the total body and face (T-VASI and F-VASI), remain unchanged.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "7151416b375efc86",
      "text": "- Global pre-launch events for Cyacelle were initiated in 2024.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "3e698471aea1b966",
      "text": "Figure 6 - Clinuvel - revenue by indication (A\\\\(m)",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "0064ff893112986f",
      "text": "Source: Company data, Jefferies estimates",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "cf8d2a8cb5535151",
      "text": "- Growth in the US: CUV talked to growth in FY25 in dose per patient - we believe this implies growth in the US, which allows for a higher number of doses. In addition, the number of patients who have received the drug has grown with the rise in Specialty Centers that are trained and accredited to administer Scenesse. This has increased. On average, we believe each Specialty Center is treating more patients and the number and frequency of orders per site has increased period-on-period.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "c17b5d5340184902",
      "text": "Figure 7 - Clinuvel - implied number of implants sold",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "b5770017eb148f8f",
      "text": "Source: Company data, Jefferies estimates",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "dc88798220d8cdd0",
      "text": "- Operating expenses increased by c28%: The increase was due to changes in personnel expenses and development expenses. Excluding capital expenditures and marketing expenses on the photo-posmetics initiative, expenses of cA\\$55m pa are planned from FY26E to FY30E.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "8b8d1dcfb684ec82",
      "text": "- Tax: In FY25, the Group had a tax expense of cA\\$18m. Hence, the effective tax rate was c30%.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "a4b797eb7b48d865",
      "text": "EPP is a rare and severe genetic disorder causing absolute UV and light intolerance in the skin. It occurs as a result of an enzyme deficiency (ferrochelatase) that allows for an abnormal build- up of protoporphyrin (a metabolite that is a part of the production of haemoglobin), a molecule toxic to the body that transforms into excited states on absorption of light energy, causing photo- oxidative",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "8c5b4ef0a8c2eb26",
      "text": "damage to the skin. This is manifested through various symptoms such as tingling, stinging, or burning and may accompany the appearance of a rash or blisters.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "041a6b8df1cefc59",
      "text": "Since June 2016, Clinuvel has distributed Scenesse to EU EPP patients through accredited Expert Centres, working within the commitments agreed with the European Medicines Agency (EMA) as a condition for continuous marketing authorisation. The distribution of Scenesse under Special Access Schemes continues to provide a preventative treatment for adult EPP patients primarily to Switzerland. Scenesse is also supplied outside Switzerland under a special access arrangement whereby CUV received full cost compensation, linked to the uniform price of Scenesse sold in Europe under the marketing authorisation.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "d4cc7c924ab8e9f8",
      "text": "On 8 October 2019, the US FDA approved Scenesse to increase pain free light exposure in adult patients with a history of phototoxic reactions from EPP. Since April 2020, CUV has been treating patients with EPP through accredited Specialty Centers in the US, in accordance with the approval of the FDA, granted in October 2019. Scenesse is accepted as First Line Therapy or (medical necessity) Standard of Care in EPP to prevent phototoxicity in the US, and hence offering systemic photoprotection. CUV believes that the US has a prevalence of EPP of 2,336 based on a US population of 327m and a prevalence of EPP of 1:140,000.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "3d9c513983c83014",
      "text": "Figure 8 - Number of EPP patients by prevalence in larger markets",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "13deb7dbdcd3ff50",
      "text": "Countryper 100KPopulation (m)No. of EPP patients in the popn.EuropeGermany0.783593UK0.867514France0.767479Italy0.760431Netherlands1.317230Switzerland0.7961AmericasUS0.73272,336Canada0.738269AsiaChina0.513936,602Japan4.01265,040Australia0.725179Total16,734",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "3241415ce1dc5234",
      "text": "Source: PubMed, US FDA, Horner, ME, et al. Int J Dermatol. 2013 Dec; 52:1464; Gouya L, et al. Am J Hum Genet 2006 Jan; 78",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "8f3abe77f6a8e7d2",
      "text": "We believe that CUV currently is treating only \\(c4\\%\\) of the EPP patients in larger countries of Europe, US and Asia. These are the countries that are close to receiving/have received regulatory approval to treat EPP patients with Scenesse. This implies that growth in the EPP indication can continue for some time.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "6151438722df8331",
      "text": "We do not believe that \\(100\\%\\) of all EPP patients in eligible markets will eventually be treated with Scenesse, but given the under- penetrated nature of the market, growth can continue for some time, in our view.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "a34a056108a4a371",
      "text": "Figure 9 - Number of EPP patients treated as a \\(\\%\\) of total in larger markets",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "9ab5a44bb61fc6c3",
      "text": "Number of EPP pts treated as a % of total in larger marketsCUV FY25A revenue (A$m)86.6A$/EUR exchange rate0.58Implied CUV FY25A revenue (EURm)50.4Assume manufacturer price of EUR14.1K per implantAssume 5 implants per patientHence, number of EPP patients treated in FY25A714No. of EPP pts treated as a % of EU/Am./ROW total (%)4.3%No. of EPP pts treated as a % of US/EU total (%)14.5%",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "75749dd10465e6e7",
      "text": "Source: Company data, Jefferies estimates",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "072ee71fa85dc65c",
      "text": "CUV's regulatory approvals in the EU (in 2014 with Orphan Drug Status) and USA (in 2019 with Orphan Drug Status) confer marketing exclusivity of ten and seven years, respectively, on Scenesse, to treat adult EPP patients. This exclusivity period is extendable by two years upon approval of a paediatric formulation of Scenesse.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "3404c5c12f36b02e",
      "text": "Figure 10 - Clinuvel - EPP revenue by geography (A\\\\(m)",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "2c0e52e2a1939599",
      "text": "Source: Company data, Jefferies estimates",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "6ff81dd16e81f903",
      "text": "Orphan drug status gives companies researching cures for rare diseases a window of tax reductions and the exclusive right to develop a cure for a specific condition. In EPP, the dosing cycle is every 60 days, with a maximum number of doses of 4 to 6 per annum, depending upon the geography.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "cdefc9d47c2d6e17",
      "text": "We believe the majority of implants are likely to be used in the summer months, when the risk of pain from sun exposure is highest. Hence, we continue to expect seasonality in CUV's earnings, with 2HFY earnings greater than 1HFY earnings.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "adbeaadb04bc927f",
      "text": "Clinuvel has adopted a uniform global pricing policy per dose. In 2017, the annual costs of therapy with Scenesee ranged between EUR56,404 and EUR84,606 per EPP patient per annum. The net price per unit of Scenesee is uniform across the jurisdictions in which it operates. Distribution costs specific to each jurisdiction determine the gross price of Scenesee. This implies pricing of EUR14.1K per implant.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "8606c7c774ea1066",
      "text": "CUV continues to work towards gaining regulatory approval for Scenesee for EPP patients in other markets, including in European countries. In Europe, CUV is working on reimbursement agreements to distribute Scenesee for EPP in more European countries, expanding the number of Expert Centres and increasing patient treatment access. In Germany, the disease affects between 500 and 1,090 patients (based on disease prevalence). Other future regions include Latin America.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "f931bbb71e87f736",
      "text": "Vitiligo is a common disorder that is characterized by white spots, typically first noted on the fingers, knuckles, around the eyes and mouth, and on the feet. In vitiligo, Scenesee is being evaluated as a. repigmentary agent and, in clinical trials to date, the drug has been administered every 28 days as an adjunct therapy to narrowband ultraviolet B (NB- UVB) phototherapy. Vitiligo affects \\(0.2\\%\\) of the US population and has minimal treatment options. The total addressable market in the US and EU is large, should the future clinical trials be successful.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "0524e28296b20f6c",
      "text": "Figure 11 - Clinuvel - Vitiligo - Total Addressable Market in the US",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "b77e38685dcd5db6",
      "text": "Vitiligo: Total Addressable Market (TAM) pa in the USPrevalence: assume 0.75% of the popn w Vitiligo, 25% of popn Fitz. IV to VI, 40% have 0.5% Body SA involvement0.25Assume only 40% seek Rx. Hence, no. pts. in the US (m)0.10Assume 8 implants per patient per treatment over c15 monthsHence, number implants required per annum (m)0.6Assume manufacturer price of US&#x27;12K per implantAssume 10% penetration of market. Hence, Vitiligo TAM (US&#x27;8bn) pa0.7Hence, Vitiligo TAM (A&#x27;8bn) per annum1.0",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "4737857520b85a30",
      "text": "Source: PubMed, Jefferies estimates",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "56704154284f5928",
      "text": "In clinical trials conducted by CUV (CUV102 and CUV103), the combination of Scenesee and narrowband ultraviolet B (NB- UVB) treatment resulted in more rapid and extensive repigmentation compared to treatment with NB- UVB alone.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "0165c4145d5eb248",
      "text": "In CUV102, a proof- of- concept study undertaken in the US, a significant recovery of pigmentation was observed in patients with darker skin complexions (Fitzpatrick skin types IV- VI). CUV's US Phase 2 study (CUV102) conducted in vitiligo showed after six months of treatment a",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "15020f25595a51ea",
      "text": "significant reduction in VASI scores \\((pIncome Statement (A$m)1H24A2H24AFY24A1H25A2H25AFY25A1H25 on 1H24 (%)2H25 on 2H24 (%)FY25 on FY24 (%)Sales revenue29.951.481.232.653.886.49.24.76.4Other revenue2.25.37.56.12.68.7174.6(51.1)15.1COGS(6.1)(4.9)(11.0)(2.4)(8.6)(11.0)Other expenses(14.2)(18.3)(32.5)(18.3)(23.2)(41.5)Operating EBITDA11.733.545.317.924.642.552.9(26.8)(6.1)Depreciation &amp;amp; Amortisation(0.6)(0.6)(1.1)(0.6)(0.6)(1.2)Operating EBIT11.133.044.117.324.041.355.4(27.3)(6.4)Other income0.00.00.00.00.000.0Net interest expense3.73.77.34.64.89.426.131.428.7Pre-tax profit14.835.950.722.828.851.653.7(19.7)1.7Tax(3.9)(11.2)(15.0)(7.9)(7.5)(15.4)Profit after tax10.924.735.614.921.336.236.3(13.9)1.5Minorities0.00.00.00.00.000.0Normalised NPAT10.924.735.614.921.336.236.3(13.9)1.5Non- recurring items0.00.00.00.00.000.0Reported profit10.924.735.614.921.336.236.3(13.9)1.5Per shareNormalised EPS (cps)21.148.469.829.242.271.838.4(12.8)2.8DPS (cps)0.05.05.00.05.05.00.00.0Average shares (mn)51.851.051.051.050.450.4(1.5)(1.3)(1.3)Ratio analysis (%)Diff (bp)Diff (bp)Diff (bp)EBITDA margin39.265.355.755.045.749.21,571-1,964-655EBIT margin37.364.254.353.144.647.81,578-1,961-651Effective tax rate26.131.129.734.526.129.8838-50215Number of units (EPP)242427669256423679",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "ed96c25ea94efcbf",
      "text": "Source: Company data, Jefferies estimates",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "07066aeacde544af",
      "text": "We have made the following changes to our forecasts:",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "b408f8d56afd6241",
      "text": "- Currency: We forecast FY26E exchange rates of 0.65 for AUD/USD and 0.56 for AUD/EUR.- Sales volume: We have updated revenue for FY26E and have updated for forecast sales into the EPP market in FY26E, particularly for penetration of the EU and US EPP markets. In the US, patients can use 6 implants per year compared to 4 in RoW. Basically, we have slowed future uptake in the US in line with what was seen in FY25.- Expenses: We have updated other cost lines for FY26E in line with FY25A.- Net interest expense: This has been re-calculated in line with period-end balances.- Tax: We assume an effective tax rate of \\(30\\%\\) in FY26E.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "38dedc563d59593e",
      "text": "Figure 14-Clinvel-Valuation Methodology",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "e04608c36e503bd8",
      "text": "Valuation of CUV R&amp;amp;D portfolioRisk-weighted valuation (A$ per share)Risk Weighting (in line with clinical trial stage) (%)Total opportunity size (A$ per share)EPP17.87100.017.87Non-segmental Vitiligo18.2761.229.85Acute Ischaemic Stroke0.3221.41.50DNA Repair (ex OTC)0.7913.45.86Total Risk-weighted valuation (A$)37.24Price Target (A$ps) (rounded)37.25",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "cc7fe0bd9654ee71",
      "text": "Source: Jefferies estimates",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "30d220622ffff08d",
      "text": "Figure 15-Clinvel-Financial Summary (A\\$m)",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "f636c85b00edf21c",
      "text": "Clinuvel focuses on developing drugs for the treatment of severe genetic and skin disorders globally. Its lead drug is Scenesse (afamelanotide), a photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). It is also pursuing the use of afamelanotide in vitiligo. The company's pipeline products include CUV9900, an alpha- melanocyte stimulating hormone analogue; VLRX001, an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity; and Penumbra, a liquid injectable formulation of afamelanotide.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "22aa6d98818cd06e",
      "text": "Our base case price target uses our risk- weighted valuations for the near- term opportunities in the CUV pipeline. In terms of valuation, there are several major potential commercial opportunities for CUV that we value: 1) EPP; 2) Vitiligo; 3) Acute Ischaemic Stroke; and 4) DNA repair. Scenesse for EPP has already been approved in the EU and US. Risks: Technology and manufacturing issues; clinical trials may not yield the expected and desired results for the products to gain further regulatory approvals; pricing issues may adversely affect revenues and profitability; patent protection not robust enough.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "6f9399b0822f1937",
      "text": "(Article 3(1)e and Article 7 of MAR) Recommendation Published Recommendation Distributed",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "810bf63df9e03e26",
      "text": "August 28, 2025 7:58 A.M. August 28, 2025 7:58 A.M.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "7f5b0587e3903bc9",
      "text": "Buy - Describes securities that we expect to provide a total return (price appreciation plus yield) of \\(15\\%\\) or more within a 12- month period. Hold - Describes securities that we expect to provide a total return (price appreciation plus yield) of plus \\(15\\%\\) or minus \\(10\\%\\) within a 12- month period. Underperform - Describes securities that we expect to provide a total return (price appreciation plus yield) of minus \\(10\\%\\) or less within a 12- month period. The expected total return (price appreciation plus yield) for Buy rated securities with an average security price consistently below \\(10\\) or more within a 12- month period as these companies are typically more volatile than the overall stock market. For Hold rated securities with an average security price consistently below \\(10\\) , the expected total return (price appreciation plus yield) is plus or minus \\(20\\%\\) within a 12- month period. For Underperform rated securities with an average security price consistently below \\(10\\) , the expected total return (price appreciation plus yield) is minus \\(20\\%\\) or less within a 12- month period.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "9edde89469907161",
      "text": "NR - The investment rating and price target have been temporarily suspended. Such suspensions are in compliance with applicable regulations and/or Jefferies policies.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "a9e57eb19c29f072",
      "text": "CS - Coverage Suspended. Jefferies has suspended coverage of this company. NC - Not covered. Jefferies does not cover this company.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "f71f9b5afba2b4e8",
      "text": "Restricted - Describes issuers where, in conjunction with Jefferies engagement in certain transactions, company policy or applicable securities regulations prohibit certain types of communications, including investment recommendations. Monitor - Describes securities whose company fundamentals and financials are being monitored, and for which no financial projections or opinions on the investment merits of the company are provided.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "2f7ce9d1532111b2",
      "text": "Jefferies methodology for assigning ratings may include the following: market capitalization, maturity, growth/value, volatility and expected total return over the next 12 months. The price targets are based on several methodologies, which may include, but are not restricted to, analyses of market risk, growth rate, revenue stream, discounted cash flow (DCF), EBITDA, EPS, cash flow (CF), free cash flow (FCF), EV/EBITDA, P/E, PE/growth, P/CF, P/FCF, premium (discount)/average group EV/EBITDA, premium (discount)/average group P/E, sum of the parts, net asset value, dividend returns, and return on equity (ROE) over the next 12 months.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "b694b512538991dd",
      "text": "Jefferies Franchise Picks include stock selections from among the best stock ideas from our equity analysts over a 12 month period. Stock selection is based on fundamental analysis and may take into account other factors such as analyst conviction, differentiated analysis, a favorable risk/reward ratio and investment themes that Jefferies analysts are recommending. Jefferies Franchise Picks will include only Buy rated stocks and the number can vary depending on analyst recommendations for inclusion. Stocks will be added as new opportunities arise and removed when the reason for inclusion changes, the stock has met its desired return, if it is no longer rated Buy and/or if it triggers a stop loss. Stocks having 120 day volatility in the bottom quartile of S&P stocks will continue to have a 15% stop loss, and the remainder will have a 20% stop. Franchise Picks are not intended to represent a recommended portfolio of stocks and is not sector based, but we may note where we believe a Pick falls within an investment style such as growth or value.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "d2fb52041fe453f3",
      "text": "- Clinvul Pharmaceuticals Ltd (CUV AU: AUD12.53, BUY)",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "e10b2d1202a2d83c",
      "text": "Notes: Each box in the Rating and Price Target History chart above represents actions over the past three years in which an analyst initiated on a company, made a change to a rating or price target of a company or discontinued coverage of a company. Legend:",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "06e3835b348cb33e",
      "text": "I: Initiating Coverage D: Dropped Coverage B: Buy H: Hold UP: Underperform",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "b6900a845481018e",
      "text": "Distribution of Ratings",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "570ec8359d134c3a",
      "text": "CountPercentCountPercentCountPercentBUY211260.69%36717.38%1175.54%HOLD121134.80%1058.67%221.82%UNDERPERFORM1574.51%31.91%31.91%",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "36c117419325c726",
      "text": "Jefries does busines and seeks to do business with companies covered in its research reports, and expects to receive or intends to seek compensation for investment banking services among other activities from such companies. As a result, investors should be aware that Jefferies may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Jefferies Equity Research refers to research reports produced by analysts employed by one of the following Jefferies Financial Group Inc. (Jefferies) companies:",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "c5649e760bc1b500",
      "text": "United States: Jefferies LLC which is an SEC registered broker- dealer and a member of FINRA (and distributed by Jefferies Research Services, LLC, an SEC registered Investment Adviser, to clients paying separately for such research).",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "52240f745afedd06",
      "text": "Canada: Jefferies Securities Inc., which is an investment dealer registered in each of the thirteen Canadian jurisdictions and a dealer member of the Canadian Investment Regulatory Organization, including research reports produced jointly by Jefferies Securities Inc. and another Jefferies entity (and distributed by Jefferies Securities Inc.).",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "f0d50cb3b607e3e9",
      "text": "Where Jefferies Securities Inc. distributes research reports produced by Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch or Jefferies India Private Limited, you are advised that each of Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch and Jefferies India Private Limited operates as a dealer in your jurisdiction under an exemption from the dealer registration requirements contained in National Instrument 31- 103 Registration Requirements, Exemptions and Ongoing Registrant Obligations and, as such, each of Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch and Jefferies India Private Limited is not required to be and is not a registered dealer or adviser in your jurisdiction. You are advised that where Jefferies LLC or Jefferies International Limited prepared this research report, it was not prepared in accordance with Canadian disclosure requirements relating to research reports in Canada.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "7a75cc9764ff1088",
      "text": "United Kingdom: Jefferies International Limited, which is authorized and regulated by the Financial Conduct Authority, registered in England and Wales No. 1978621; registered office: 100 Bishopsgate, London EC2N 4JL; telephone +44 (0)20 7029 8000; facsimile +44 (0)20 7029 8010.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "a02b6a76b20b2b8d",
      "text": "Japan: Jefferies (Japan) Limited, Tokyo Branch, which is a securities company registered by the Financial Services Agency of Japan and is a member of the Japan Securities Dealers Association; located at Tokyo Midtown Hibiya 30F Hibiya Mitsui Tower, 1- 1- 2 Yurakucho, Chiyoda- ku, Tokyo 100- 0006; telephone +813 5251 6100; facsimile +813 5251 6101.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "c2f945972e1d68a3",
      "text": "Australia: Jefferies (Australia) Pty Limited (ACN 623 059 898), which holds an Australian financial services license (AFSL 504712) and is located at Level 20, 60 Martin Place, Sydney NSW 2000; telephone +61 2 9364 2800.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "3b56b8c474704c05",
      "text": "Dubai: Jefferies International Limited, Dubai branch, which is licensed by the Dubai Financial Services Authority (DFSA Reference Number F007325); registered office Unit L31- 06, L31- 07, Level 31, ICD Brookfield Pace, DIFC, PO Box 121208, Dubai, UAE.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "32f67e5dc352fe1d",
      "text": "This report was prepared by personnel who are associated with Jefferies (Jefferies Securities Inc., Jefferies International Limited, Jefferies GmbH, Jefferies Hong Kong Limited, Jefferies Singapore Limited, Jefferies (Japan) Limited, Tokyo Branch, Jefferies India Private Limited), and Jefferies (Australia) Pty Ltd; or by personnel who are associated with both Jefferies LLC and Jefferies Research Services LLC (\"JRS\"). Jefferies LLC is a US registered broker- dealer and is affiliated with JRS, which is a US registered investment adviser. JRS does not create tailored or personalized research and all research provided by JRS is impersonal. If you are paying separately for this research, it is being provided to you by JRS. Otherwise, it is being provided by Jefferies LLC. Jefferies LLC, JRS, and their affiliates are collectively referred to below as \"Jefferies\". Jefferies may seek to do business with companies covered in this research report. As a result, investors should be aware that Jefferies may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only one of many factors in making their investment decisions. Specific conflict of interest and other disclosures that are required by FINRA, the Canadian Investment Regulatory Organization and other rules are set forth in this disclosure section.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "5b70733e31d1ba05",
      "text": "If you are receiving this report from a non- US Jefferies entity, please note the following: Unless prohibited by the provisions of Regulation S of the U.S. Securities Act of 1933, as amended, this material is distributed in the United States by Jefferies LLC, which accepts responsibility for its contents in accordance with the provisions of Rule 15a- 6 under the US Securities Exchange Act of 1934, as amended. Transactions by or on behalf of any US person may only be effected through Jefferies LLC. In the United Kingdom and European Economic Area this report is issued and/or approved for distribution by Jefferies International Limited (\"JIL\") and/or Jefferies GmbH and is intended for use only by persons who have, or have been assessed as having, suitable professional experience and expertise, or by persons to whom it can be otherwise lawfully distributed. Jefferies LLC, JIL, Jefferies GmbH and their affiliates, may make a market or provide liquidity in the financial instruments referred to in this report; and where they do make a market, such activity is disclosed specifically in this report under \"company specific disclosures\".",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "6b30a94386613a37",
      "text": "For Canadian investors, this material is intended for use only by professional or institutional investors. None of the investments or investment services mentioned or described herein is available to other persons or to anyone in Canada who is not a \"permitted client\" as defined by National Instrument 31- 103 Registration Requirements, Exemptions and Ongoing Registrant Obligations, as applicable. This research report is a general discussion of the merits and",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "3f962e0411598039",
      "text": "first considering whether any advice or recommendation in this report is suitable for the recipient based on the recipient's particular circumstances and, if appropriate or otherwise needed, seeking professional advice, including tax advice. Jefferies does not perform any suitability or other analysis to check whether an investment decision made by the recipient based on this report is consistent with a recipient's investment objectives, portfolio holdings, strategy, financial situation, or needs.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "39f48e79132c82aa",
      "text": "By providing this report, neither JRS nor any other Jefferies entity accepts any authority, discretion, or control over the management of the recipient's assets. Any action taken by the recipient of this report, based on the information in the report, is at the recipient's sole judgment and risk. The recipient must perform his or her own independent review of any prospective investment. If the recipient uses the services of Jefferies LLC (or other affiliated broker- dealers), in connection with a purchase or sale of a security that is a subject of these materials, such broker- dealer may act as principal for its own accounts or as agent for another person. Only JRS is registered with the SEC as an investment adviser; and therefore neither Jefferies LLC nor any other Jefferies affiliate has any fiduciary duty in connection with distribution of these reports.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "b8b68ea52524afd0",
      "text": "The price and value of the investments referred to herein and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "3bccfd2b915c54d3",
      "text": "This report may contain forward looking statements that may be affected by inaccurate assumptions or by known or unknown risks, uncertainties, and other important factors. As a result, the actual results, events, performance or achievements of the financial product may be materially different from those expressed or implied in such statements.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "74c8afd175ef48e9",
      "text": "This report has been prepared independently of any issuer of securities mentioned herein and not as agent of any issuer of securities. No Equity Research personnel have authority whatsoever to make any representations or warranty on behalf of the issuer(s). Any comments or statements made herein are those of the Jefferies entity producing this report and may differ from the views of other Jefferies entities.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "e0686f27d457b120",
      "text": "This report may contain information obtained from third parties, including ratings from credit ratings agencies such as Standard & Poor's, and information derived from third- party or proprietary generative artificial intelligence (Gen AI) models. Jefferies does not guarantee the accuracy, completeness, timeliness or availability of this information, and is not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Neither Jefferies nor any third- party content providers, including providers of Gen AI models, give any express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Neither Jefferies nor any third- party content provider shall be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs,",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "72f1f7ad1977fe75",
      "text": "expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content, including ratings. Credit ratings are statements of opinions and are not statements of fact or recommendations to purchase, hold or sell securities. They do not address the suitability of securities or the suitability of securities for investment purposes, and should not be relied on as investment advice. Reproduction and distribution of third party content in any form is prohibited except with the prior written permission of the related third party.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "efb2facaa4281b8f",
      "text": "Jefferies research reports are disseminated and available electronically, and, in some cases, also in printed form. Electronic research is simultaneously made available to all clients. This report or any portion hereof may not be copied, reprinted, sold, or redistributed or disclosed by the recipient or any third party, by content scraping or extraction, automated processing, or any other form or means, without the prior written consent of Jefferies. Any unauthorized use is prohibited. Neither Jefferies nor any of its respective directors, officers or employees, is responsible for guaranteeing the financial success of any investment, or accepts any liability whatsoever for any direct, indirect or consequential damages or losses arising from any use of this report or its contents. Nothing herein shall be construed to waive any liability Jefferies has under applicable U.S. federal or state securities laws.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "0ba6fa2345e69586",
      "text": "For Important Disclosure information relating to JRS, please see https://adviserinfo.sec.gov/lAPD/Content/Common/crd_iapd_Brochure.aspx? BRCHR_VRSN_ID=483878 and https://adviserinfo.sec.gov/Firm/292142 or visit our website at https://javatar.bluematrix.com/sellside/Disclosures.action, or www.jefferies.com, or call 1.888. JEFFERIES.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "18354035e2da9059",
      "text": "\\(①\\) 2025 Jefferies",
      "page": 14,
      "section": null
    }
  ],
  "entities": [
    {
      "entity_id": "e675a2a919248a8b",
      "name": "Acute Ischaemic",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "146914ba3f2b493a",
      "name": "Australian Healthcare",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "091ea27f0512d847",
      "name": "Base Case",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "1cecd38d66ed031f",
      "name": "Biotechnology  Clinuvel",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "ddfa5cb820855f7a",
      "name": "Body SA",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "7860a2554c61a53f",
      "name": "Canadian Investment",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "4b7a84782086f6c1",
      "name": "Clinuvel\n\nClinuvel",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "ce6413c99c6d2f77",
      "name": "Clinuvel\n\nOur",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "381a445a54cb2be8",
      "name": "Clinvul Pharmaceuticals",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "cbd7c12cebfc309a",
      "name": "Clinvul Pharmaceuticals Ltd",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "6e4788dbad025b7b",
      "name": "Company Description",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "a92ba89b9eff6c1b",
      "name": "Company Target",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "8bb7d9a681cb9e40",
      "name": "Company Valuation",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "4b9be408e155a05b",
      "name": "Coverage Suspended",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "e9cd18ef1469e32c",
      "name": "DFSA Reference",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "803b148ffb44df85",
      "name": "DNA Repair",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "6ba4b0a762d135f4",
      "name": "Dealers Association",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "d8af45e434b16fef",
      "name": "Deep Dive",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "712df7514f4cbc80",
      "name": "Differ\n\nCUV",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "e736f0c0f1f7561e",
      "name": "Disclosures\n\nJefries",
      "type": "company",
      "aliases": []
    }
  ],
  "data": {
    "figures": [
      {
        "type": "pie",
        "title": null,
        "page": 1,
        "axes": {},
        "series": [
          {
            "name": "Other (OTC)",
            "unit": "%",
            "values": [
              2.1
            ]
          },
          {
            "name": "Acute Ischaemic Stroke",
            "unit": "%",
            "values": [
              0.9
            ]
          },
          {
            "name": "Non-segmental Vitiligo",
            "unit": "%",
            "values": []
          },
          {
            "name": "EPF",
            "unit": "%",
            "values": [
              48
            ]
          }
        ],
        "figure_id": "b67aae6caa1b1384",
        "provenance": {
          "page": 1
        }
      },
      {
        "type": "combo",
        "title": null,
        "page": 1,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "1H19A",
              "2H19A",
              "1H20A",
              "2H20A",
              "1H21A",
              "2H21A",
              "1H22A",
              "2H22A",
              "1H23A",
              "2H23A",
              "1H24A",
              "2H24A",
              "1H25A",
              "2H25A",
              "1H26E",
              "2H26E"
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0,
              "max": 500
            }
          }
        },
        "series": [
          {
            "name": "Implied number of implants sold",
            "unit": null,
            "values": [
              74,
              207,
              73,
              199,
              126,
              270,
              201,
              336,
              240,
              397,
              242,
              427,
              256,
              423,
              262,
              446
            ]
          },
          {
            "name": "Growth on pcp (%) (RHS)",
            "unit": "%",
            "values": [
              5,
              5,
              0,
              -5,
              45,
              25,
              15,
              20,
              10,
              5,
              0,
              5,
              10,
              0,
              5,
              10
            ]
          }
        ],
        "figure_id": "14c044b531e6ea9d",
        "provenance": {
          "page": 1
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 2,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "2024",
              "2025",
              "+12 mo."
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0,
              "max": 60
            }
          }
        },
        "series": [
          {
            "name": "Historical Data",
            "unit": null,
            "values": [
              {
                "x": "start_2024",
                "y": 20
              },
              {
                "x": "mid_2024",
                "y": 15
              },
              {
                "x": "end_2024",
                "y": 12
              },
              {
                "x": "mid_2025",
                "y": 10
              },
              {
                "x": "end_2025",
                "y": 13
              }
            ]
          },
          {
            "name": "Upside Forecast",
            "unit": null,
            "values": [
              {
                "x": "end_2025",
                "y": 13
              },
              {
                "x": "+12 mo.",
                "y": 55.07
              }
            ]
          },
          {
            "name": "Mid Forecast",
            "unit": null,
            "values": [
              {
                "x": "end_2025",
                "y": 13
              },
              {
                "x": "+12 mo.",
                "y": 37.25
              }
            ]
          },
          {
            "name": "Downside Forecast",
            "unit": null,
            "values": [
              {
                "x": "end_2025",
                "y": 13
              },
              {
                "x": "+12 mo.",
                "y": 7.45
              }
            ]
          }
        ],
        "figure_id": "c4249db516b89a61",
        "provenance": {
          "page": 2
        }
      },
      {
        "type": "other",
        "title": "FY25: The Warmth of the Sun",
        "page": 3,
        "axes": {},
        "series": [],
        "figure_id": "c027f8cc1a9af350",
        "provenance": {
          "page": 3
        }
      },
      {
        "type": "bar",
        "title": null,
        "page": 4,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "FY20A",
              "FY21A",
              "FY22A",
              "FY23E",
              "FY24E",
              "FY25E",
              "FY26E",
              "FY27E",
              "FY28E",
              "FY29E",
              "FY30E"
            ]
          },
          "y": {
            "unit": "A$m",
            "range": {
              "min": 0,
              "max": 800
            }
          }
        },
        "series": [
          {
            "name": "EPP",
            "unit": "A$m",
            "values": [
              20,
              30,
              50,
              70,
              80,
              90,
              100,
              110,
              120,
              125,
              135
            ]
          },
          {
            "name": "Non-segmental Vitiligo",
            "unit": "A$m",
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              5,
              150,
              300,
              400
            ]
          },
          {
            "name": "AIS",
            "unit": "A$m",
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              50,
              100,
              120
            ]
          },
          {
            "name": "DNA Repair",
            "unit": "A$m",
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              80,
              120,
              150
            ]
          }
        ],
        "figure_id": "2fdff703f0ac252f",
        "provenance": {
          "page": 4
        }
      },
      {
        "type": "combo",
        "title": null,
        "page": 4,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "1H19A",
              "2H19A",
              "1H20A",
              "2H20A",
              "1H21A",
              "2H21A",
              "1H22A",
              "2H22A",
              "1H23A",
              "2H23A",
              "1H24A",
              "2H24A",
              "1H25A",
              "2H25E"
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0,
              "max": 600
            }
          }
        },
        "series": [
          {
            "name": "Implied number of implants sold",
            "unit": null,
            "values": [
              74,
              207,
              73,
              199,
              126,
              270,
              201,
              336,
              240,
              397,
              243,
              440,
              258,
              482
            ]
          },
          {
            "name": "Growth on pcp (%) (RHS)",
            "unit": "%",
            "values": [
              0.05,
              0.05,
              0.02,
              0.05,
              0.55,
              0.25,
              0.48,
              0.25,
              0.2,
              0.2,
              0.05,
              0.1,
              0.1,
              0.1
            ]
          }
        ],
        "figure_id": "22f6d39781ee8d48",
        "provenance": {
          "page": 4
        }
      },
      {
        "type": "bar",
        "title": null,
        "page": 6,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "2016A",
              "2017A",
              "2018A",
              "2019A",
              "2020A",
              "2021A",
              "2022A",
              "2023A",
              "2024A",
              "2025A",
              "2026E",
              "2027E",
              "2028E"
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0,
              "max": 1000
            }
          }
        },
        "series": [
          {
            "name": "Northern America",
            "unit": null,
            "values": [
              0,
              0,
              0,
              0,
              0,
              60,
              150,
              180,
              200,
              205,
              220,
              245,
              290
            ]
          },
          {
            "name": "European Union (EU-6)",
            "unit": null,
            "values": [
              10,
              130,
              230,
              290,
              280,
              330,
              380,
              440,
              450,
              460,
              470,
              480,
              490
            ]
          },
          {
            "name": "Rest of World",
            "unit": null,
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          }
        ],
        "figure_id": "c1d3e49a2cb6f2de",
        "provenance": {
          "page": 6
        }
      },
      {
        "type": "line",
        "title": "Rating and Price Target History for: Clinuvel Pharmaceuticals Ltd (CUV AU) as of 08-27-2025",
        "page": 11,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Oct 22",
              "Jan 23",
              "Apr 23",
              "Jul 23",
              "Oct 23",
              "Jan 24",
              "Apr 24",
              "Jul 24",
              "Oct 24",
              "Jan 25",
              "Apr 25",
              "Jul 25"
            ]
          },
          "y": {
            "unit": "AUD",
            "range": {
              "min": 5,
              "max": 30
            }
          }
        },
        "series": [
          {
            "name": "Price",
            "unit": "AUD",
            "values": [
              18.5,
              20.5,
              27.5,
              20.0,
              17.0,
              15.0,
              16.0,
              13.0,
              11.0,
              10.0,
              11.5,
              14.0
            ]
          },
          {
            "name": "Target Price",
            "unit": "AUD",
            "values": [
              {
                "date": "08/30/2022",
                "value": 36.9
              },
              {
                "date": "01/24/2023",
                "value": 38.6
              },
              {
                "date": "02/24/2023",
                "value": 37.3
              },
              {
                "date": "07/17/2023",
                "value": 36.8
              },
              {
                "date": "08/29/2023",
                "value": 35.8
              },
              {
                "date": "10/18/2023",
                "value": 50.3
              },
              {
                "date": "01/11/2024",
                "value": 47.85
              },
              {
                "date": "02/21/2024",
                "value": 46.3
              },
              {
                "date": "07/16/2024",
                "value": 46.35
              },
              {
                "date": "08/21/2024",
                "value": 39.7
              },
              {
                "date": "08/28/2024",
                "value": 39.6
              },
              {
                "date": "01/16/2025",
                "value": 39.2
              },
              {
                "date": "02/27/2025",
                "value": 39.45
              },
              {
                "date": "07/17/2025",
                "value": 40.0
              }
            ]
          }
        ],
        "figure_id": "2fccdb74d81f6347",
        "provenance": {
          "page": 11
        }
      }
    ],
    "tables": [],
    "numerical_data": [
      {
        "num_id": "d999117eba6426d5",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ude growth in the Americas, as well as ongoing clinical trials in vitiligo. FY25 volume growth was c1%. That said, we forecast volume growth of 4% for FY26E, as CUV will enter two EU geographies in FY",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "1706ef7c8445c6e4",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ng clinical trials in vitiligo. FY25 volume growth was c1%. That said, we forecast volume growth of 4% for FY26E, as CUV will enter two EU geographies in FY26E. We expect first results from the CUV105",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "564e7a4cc92db79c",
        "value": 0.0075,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "no competitors at present; and 2) currently in Phase 3 clinical trial with vitiligo, which affects c0.75% of the US population with current treatment options suboptimal. We believe that CUV currently ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "40e151bab611bc8c",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "pulation with current treatment options suboptimal. We believe that CUV currently is treating only c4% of the EPP patients in larger countries of Europe, Americas and Asia (c15% of EU and Americas), a",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "00e0d8ebef8fa218",
        "value": 0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "rrently is treating only c4% of the EPP patients in larger countries of Europe, Americas and Asia (c15% of EU and Americas), a situation which should be progressively corrected through ongoing local a",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "7806a6d4ced1c70c",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "solution than current standards of care. FY25 normalised net profit of \\(\\Delta\\) 36.2m increased c2% from the previous corresponding period (pcp), with higher costs. FY25 sales revenue increased c6% ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "469b9b658b65de2e",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "c2% from the previous corresponding period (pcp), with higher costs. FY25 sales revenue increased c6% on pcp to A\\\\$86.4m. This translated to an estimated c1% increase in volume in FY25 compared to pc",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "63437147e404ac1e",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "igher costs. FY25 sales revenue increased c6% on pcp to A\\\\$86.4m. This translated to an estimated c1% increase in volume in FY25 compared to pcp. We forecast 4% volume growth for FY26E. Opportunity c",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "1da9b84e9f0301f8",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "$86.4m. This translated to an estimated c1% increase in volume in FY25 compared to pcp. We forecast 4% volume growth for FY26E. Opportunity continues in the US. The number of patients who have receive",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "b6717003e81537b4",
        "value": 0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "industry experts, and hence would ideally standard treatment as children. FY26E EPS decreases by c15%, FY27E EPS decreases by c20%. Changes to forecasts include: 1) updating for forecast sales into th",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "e804f1b990ee44f7",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "would ideally standard treatment as children. FY26E EPS decreases by c15%, FY27E EPS decreases by c20%. Changes to forecasts include: 1) updating for forecast sales into the EPP market in FY26E+, part",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "3e7f8e2cedecee96",
        "value": 1.97,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>PRICE</td><td>AUD12.53*</td></tr><tr><td>PRICE TARGET | % TO PT</td><td>+ AUD37.25 (AUD40.00) | +197%</td></tr><tr><td>52W HIGH-LOW</td><td>AUD15.99 - AUD9.41</td></tr><tr><td>FLOAT (%) | ADV MM (",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "e2b0651358d7d96d",
        "value": 0.7879999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "r><tr><td>52W HIGH-LOW</td><td>AUD15.99 - AUD9.41</td></tr><tr><td>FLOAT (%) | ADV MM (USD)</td><td>78.8% | 1.24</td></tr><tr><td>MARKET CAP</td><td>AUD631.3M | $409.4M</td></tr><tr><td>TICKER</td><td",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "4079df492841f3dc",
        "value": -0.11,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "O JEFE</td><td>JEF vs CONS</td></tr><tr><td></td><td>2026</td><td>2027</td></tr><tr><td>REV</td><td>-11%</td><td>-14%</td></tr><tr><td>EPS</td><td>-15%</td><td>-21%</td></tr><tr><td></td><td></td><td>",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "daacd38830500084",
        "value": -0.14,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>JEF vs CONS</td></tr><tr><td></td><td>2026</td><td>2027</td></tr><tr><td>REV</td><td>-11%</td><td>-14%</td></tr><tr><td>EPS</td><td>-15%</td><td>-21%</td></tr><tr><td></td><td></td><td>-3%</td></tr>",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "398d9ecc3f499f0f",
        "value": -0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>2026</td><td>2027</td></tr><tr><td>REV</td><td>-11%</td><td>-14%</td></tr><tr><td>EPS</td><td>-15%</td><td>-21%</td></tr><tr><td></td><td></td><td>-3%</td></tr><tr><td>2026 (AUD)</td><td>1Half</",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "4538a99b5b004e91",
        "value": -0.21,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>2027</td></tr><tr><td>REV</td><td>-11%</td><td>-14%</td></tr><tr><td>EPS</td><td>-15%</td><td>-21%</td></tr><tr><td></td><td></td><td>-3%</td></tr><tr><td>2026 (AUD)</td><td>1Half</td><td>2Half<",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "0a3ecdf2bdabe27e",
        "value": -0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "-11%</td><td>-14%</td></tr><tr><td>EPS</td><td>-15%</td><td>-21%</td></tr><tr><td></td><td></td><td>-3%</td></tr><tr><td>2026 (AUD)</td><td>1Half</td><td>2Half</td></tr><tr><td>EPS</td><td>+0.28</td><",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "8d95ca228f6820b5",
        "value": 500.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "approvals. Vitiligo is a regimentation disease with a large total addressable market of up to cUS\\\\$500m in the first two years of entry into the US market. Given Phase 2 trial results, we believe afa",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "30271343c2fbb56b",
        "value": 86.4,
        "unit": "$",
        "metric_type": "currency",
        "context": "evious corresponding period (pcp), with higher costs. FY25 sales revenue increased c6% on pcp to A\\\\$86.4m. This translated to an estimated c1% increase in volume in FY25 compared to pcp. We forecast ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "9b433417c9eb0ee9",
        "value": 37.25,
        "unit": "$",
        "metric_type": "currency",
        "context": "6E+ COGS in line with FY25; and 4) Updating other cost lines for FY26E+ in line with FY25. FY16 A\\\\$37.25 (from A\\\\$40). We use our risk- weighted valuation of the CUV current EPP rollout and vitiligo",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "ce043a2671c03cc4",
        "value": 40.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "with FY25; and 4) Updating other cost lines for FY26E+ in line with FY25. FY16 A\\\\$37.25 (from A\\\\$40). We use our risk- weighted valuation of the CUV current EPP rollout and vitiligo opportunity as o",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "defbc47f83a7a334",
        "value": 409400000.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "r><td>FLOAT (%) | ADV MM (USD)</td><td>78.8% | 1.24</td></tr><tr><td>MARKET CAP</td><td>AUD631.3M | $409.4M</td></tr><tr><td>TICKER</td><td>CUV AU</td></tr></table> \\\\*Prior trading day's closing pric",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "c0052e9ec7947dad",
        "value": 1.97,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Figure 1-0](images/1_0.jpg) <center>Risk/Reward - 12 Month View </center> ## Base Case, AUD37.25, +197% Our base case price target uses our risk- weighted valuations for the near- term opportunities i",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "72ab61dfd67d8e7a",
        "value": 3.4,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "atment. Scenesce for EPP has already been approved in the EU and US. ## Upside Scenario, AUD55.07, +340% Our upside case price target is a non- risk weighted valuation for our valuation of CUV's base-",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "8cd889b4e28de691",
        "value": -0.41,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "hted valuation for our valuation of CUV's base- case opportunities. ## Downside Scenario, AUD7.45, -41% Our downside case price target assumes: 1) the clinical trial in vitiligo fails; and 2) a \\(50\\%",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "8f83df731c31c18f",
        "value": 0.98,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>42</td><td>45</td><td>159</td></tr><tr><td>JEF NPAT/consensus (%)</td><td>na</td><td>na</td><td>98%</td><td>89%</td><td>155%</td></tr><tr><td>Full diluted norm EPS</td><td>0.70</td><td>0.72</td><t",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "1f0599a63af126a6",
        "value": 0.89,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>45</td><td>159</td></tr><tr><td>JEF NPAT/consensus (%)</td><td>na</td><td>na</td><td>98%</td><td>89%</td><td>155%</td></tr><tr><td>Full diluted norm EPS</td><td>0.70</td><td>0.72</td><td>0.83</td><",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "ab33cf799ecb76a8",
        "value": 1.55,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>159</td></tr><tr><td>JEF NPAT/consensus (%)</td><td>na</td><td>na</td><td>98%</td><td>89%</td><td>155%</td></tr><tr><td>Full diluted norm EPS</td><td>0.70</td><td>0.72</td><td>0.83</td><td>0.89</td>",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "97fa757f1d36492b",
        "value": 0.043,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "in FY25A</td><td>714</td></tr><tr><td>No. of EPP pts treated as a % of EU/Am./ROW total (%)</td><td>4.3%</td></tr><tr><td>No. of EPP pts treated as a % of US/EU total (%)</td><td>14.5%</td></tr></tabl",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "64b61da1d9bab54d",
        "value": 0.145,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "OW total (%)</td><td>4.3%</td></tr><tr><td>No. of EPP pts treated as a % of US/EU total (%)</td><td>14.5%</td></tr></table> Source:Company data,Jefferies estimates ## No guidance, but catalysts in FY2",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "f9612b0f127db4ba",
        "value": 86.4,
        "unit": "$",
        "metric_type": "currency",
        "context": "feries estimates,company data ## Result summary FY25 sales revenue increased \\(c6\\%\\) on pcp to A\\$86.4m. The main drivers of the result were solid FY25 revenue growth, offset by higher costs than exp",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "95bcbc307f04e4c3",
        "value": 36.2,
        "unit": "$",
        "metric_type": "currency",
        "context": "with preparation for a potential vitiligo indication for Scenesce). FY25 normalised net profit of A\\$36.2m increased \\(c1.5\\%\\) from the previous corresponding period (pcp). FY25 normalised EPS of A\\$",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "6d93c1a0208d5073",
        "value": 0.718,
        "unit": "$",
        "metric_type": "currency",
        "context": "\\$36.2m increased \\(c1.5\\%\\) from the previous corresponding period (pcp). FY25 normalised EPS of A\\$0.718 increased \\(c3\\%\\) on pcp. FY25 operating cash flow was A\\$41.1m. Figure 5-Number of EPP pati",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "2842df3ab84ce07e",
        "value": 41.1,
        "unit": "$",
        "metric_type": "currency",
        "context": "od (pcp). FY25 normalised EPS of A\\$0.718 increased \\(c3\\%\\) on pcp. FY25 operating cash flow was A\\$41.1m. Figure 5-Number of EPP patients treated as a \\(\\%\\) of total in larger markets <table><tr><t",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "68f5c54e10c4d348",
        "value": 0.28,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "r> <center>Source: Company data, Jefferies estimates </center> - Operating expenses increased by c28%: The increase was due to changes in personnel expenses and development expenses. Excluding capital",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "fb136766897e0629",
        "value": 0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "FY30E. - Tax: In FY25, the Group had a tax expense of cA\\$18m. Hence, the effective tax rate was c30%. ## 1. CUV's opportunities: Erythropoietic Protoporphyria EPP is a rare and severe genetic disord",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "1d52a59764456f32",
        "value": 55.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "uding capital expenditures and marketing expenses on the photo-posmetics initiative, expenses of cA\\$55m pa are planned from FY26E to FY30E. - Tax: In FY25, the Group had a tax expense of cA\\$18m. Hen",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "9ba93521832f9911",
        "value": 18.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "s of cA\\$55m pa are planned from FY26E to FY30E. - Tax: In FY25, the Group had a tax expense of cA\\$18m. Hence, the effective tax rate was c30%. ## 1. CUV's opportunities: Erythropoietic Protoporphyri",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "373b609cf8645fd3",
        "value": 0.043,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "in FY25A</td><td>714</td></tr><tr><td>No. of EPP pts treated as a % of EU/Am./ROW total (%)</td><td>4.3%</td></tr><tr><td>No. of EPP pts treated as a % of US/EU total (%)</td><td>14.5%</td></tr></tabl",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "749cc37467dc5e7f",
        "value": 0.145,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "OW total (%)</td><td>4.3%</td></tr><tr><td>No. of EPP pts treated as a % of US/EU total (%)</td><td>14.5%</td></tr></table> Source: Company data, Jefferies estimates CUV's regulatory approvals in the ",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "a0375425e4c53f54",
        "value": 0.0075,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "lspan=\"2\">Vitiligo: Total Addressable Market (TAM) pa in the US</td></tr><tr><td>Prevalence: assume 0.75% of the popn w Vitiligo, 25% of popn Fitz. IV to VI, 40% have 0.5% Body SA involvement</td><td>",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "193cdf125e3149b1",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "essable Market (TAM) pa in the US</td></tr><tr><td>Prevalence: assume 0.75% of the popn w Vitiligo, 25% of popn Fitz. IV to VI, 40% have 0.5% Body SA involvement</td><td>0.25</td></tr><tr><td>Assume o",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "e7eb28cd3cea2145",
        "value": 0.4,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "he US</td></tr><tr><td>Prevalence: assume 0.75% of the popn w Vitiligo, 25% of popn Fitz. IV to VI, 40% have 0.5% Body SA involvement</td><td>0.25</td></tr><tr><td>Assume only 40% seek Rx. Hence, no. ",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "0195d07de2ee5fa1",
        "value": 0.005,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "></tr><tr><td>Prevalence: assume 0.75% of the popn w Vitiligo, 25% of popn Fitz. IV to VI, 40% have 0.5% Body SA involvement</td><td>0.25</td></tr><tr><td>Assume only 40% seek Rx. Hence, no. pts. in t",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "46657ba45aec6cc3",
        "value": 0.4,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "of popn Fitz. IV to VI, 40% have 0.5% Body SA involvement</td><td>0.25</td></tr><tr><td>Assume only 40% seek Rx. Hence, no. pts. in the US (m)</td><td>0.10</td></tr><tr><td>Assume 8 implants per patie",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "afaef2bb10f88985",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "></tr><tr><td>Assume manufacturer price of US&#x27;12K per implant</td><td></td></tr><tr><td>Assume 10% penetration of market. Hence, Vitiligo TAM (US&#x27;8bn) pa</td><td>0.7</td></tr><tr><td>Hence, ",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "e2d9b0824052dbd8",
        "value": 0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "loss. Stocks having 120 day volatility in the bottom quartile of S&P stocks will continue to have a 15% stop loss, and the remainder will have a 20% stop. Franchise Picks are not intended to represent",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "567546b6b429a58d",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "bottom quartile of S&P stocks will continue to have a 15% stop loss, and the remainder will have a 20% stop. Franchise Picks are not intended to represent a recommended portfolio of stocks and is not ",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "bd710054f1825b29",
        "value": 0.6069,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>Count</td><td>Percent</td><td>Count</td><td>Percent</td></tr><tr><td>BUY</td><td>2112</td><td>60.69%</td><td>367</td><td>17.38%</td><td>117</td><td>5.54%</td></tr><tr><td>HOLD</td><td>1211</td><",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "19cddc8ed6f225d4",
        "value": 0.17379999999999998,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>Count</td><td>Percent</td></tr><tr><td>BUY</td><td>2112</td><td>60.69%</td><td>367</td><td>17.38%</td><td>117</td><td>5.54%</td></tr><tr><td>HOLD</td><td>1211</td><td>34.80%</td><td>105</td><",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "d7daaa53ab24fc9d",
        "value": 0.0554,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ent</td></tr><tr><td>BUY</td><td>2112</td><td>60.69%</td><td>367</td><td>17.38%</td><td>117</td><td>5.54%</td></tr><tr><td>HOLD</td><td>1211</td><td>34.80%</td><td>105</td><td>8.67%</td><td>22</td><td",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "6a137bdd6288ea81",
        "value": 0.348,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "69%</td><td>367</td><td>17.38%</td><td>117</td><td>5.54%</td></tr><tr><td>HOLD</td><td>1211</td><td>34.80%</td><td>105</td><td>8.67%</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>157<",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "91d86855a7d8f1b3",
        "value": 0.0867,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "38%</td><td>117</td><td>5.54%</td></tr><tr><td>HOLD</td><td>1211</td><td>34.80%</td><td>105</td><td>8.67%</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>157</td><td>4.51%</td><td>3</td",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "3173741a92723c06",
        "value": 0.0182,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ".54%</td></tr><tr><td>HOLD</td><td>1211</td><td>34.80%</td><td>105</td><td>8.67%</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>157</td><td>4.51%</td><td>3</td><td>1.91%</td><td>3</td>",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "c7c5c1c4852f8f0f",
        "value": 0.0451,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>105</td><td>8.67%</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>157</td><td>4.51%</td><td>3</td><td>1.91%</td><td>3</td><td>1.91%</td></tr></table><｜end▁of▁sentence｜>",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "17611ea6a815b99b",
        "value": 0.0191,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>157</td><td>4.51%</td><td>3</td><td>1.91%</td><td>3</td><td>1.91%</td></tr></table><｜end▁of▁sentence｜>",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "1b40fca233931134",
        "value": 0.0191,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td></tr><tr><td>UNDERPERFORM</td><td>157</td><td>4.51%</td><td>3</td><td>1.91%</td><td>3</td><td>1.91%</td></tr></table><｜end▁of▁sentence｜>",
        "provenance": {
          "page": 11
        }
      }
    ],
    "claims": [],
    "relations": [],
    "extraction_summary": {
      "figures_count": 8,
      "tables_count": 0,
      "numerical_data_count": 58,
      "passages_count": 122,
      "entities_count": 20
    }
  }
}